Drugs / IBI3035
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07591519 | May 2026 → Jul 2027 expected | — | Innovent Biologics (Suzhou) Co. Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IBI3035 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07591519 ↗ |
| Route | Subcutaneous | “IBI3035 administered subcutaneously(SC)” NCT07591519 ↗ |